Key facts
- Relief Cardiovascular’s last known valuation is $24.5M (Dec 2024).
- It has raised $13.5M; the latest was Early Stage VC ($12.0M) in Dec 2024.
- Notable investors include MedTech Innovator, Good Growth Capital, Advent Life Sciences, Broadview Ventures, Minogue Consulting — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Relief Cardiovascular
- ·The full record, as it builds
Funding rounds
No funding rounds for Relief Cardiovascular are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Relief Cardiovascular
Developer of a new implantable device designed to treat congestive heart failure. The company's device monitors and modulates blood flow and is intended to reduce congestion in the heart and potentially improve outcomes for patients with this condition, enabling patients with heart failure to receive proper treatment.
- Sector
- Healthcare
- HQ
- Costa Mesa, CA, United States
- Founded
- 2022
- Employees
- 10
- Website
- reliefcardio.com/
- Ownership
- Privately Held (backing)
Relief Cardiovascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Relief Cardiovascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Relief Cardiovascular in its N-PORT filings yet. We sweep new filings monthly.